• main image

    Avant-Garde Therapy for Intractable Diseases

    The World’s First PEGylated Bilirubin Technology

Leadership

arrow_forward

Our Technology

arrow_forward

Our Identity

Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business platform such as contrast agents for cancer diagnostics, and theranostics.

Ingenious Platform with PEGylated Bilirubin

BRIXELLE Platform is based on a proprietary technology and can be used to cure many intractable inflammatory diseases. It also can be developed into a highly potent and less toxic anti-cancer drug delivery system and other theranostics applications.

Latest news

Bilix: Korean Biotech Startup Unveils Breakthrough PEGylated Bilirubin Technology

Bilix, a pioneering Korean biotech startup, is capturing global attention with its revolutionary PEGylated bilirubin technology. Known as Brixelle®, this cutting-edge platform promises to transform the treatment landscape for inflammatory diseases and

엠아이텍, 빌릭스와 항염증 약물방출형 생분해성 스텐트 공동 연구개발

비혈관용 스텐트 제조 기업 엠아이텍이 차세대 염증치료 물질로 주목 받는 ‘빌리루빈’을 약제화 하는데 성공한 빌릭스와 공동 연구개발 협약(MOU)을 체결했다고 28일 밝혔다. 빌릭스는 빌리루빈을 약제화 하기 위해 전상용 한국과학기술원(KAIST) 생명과학과 교수와 김명립

[바이오임팩트]김명립 빌릭스 대표…”신약개발 도전, 빌리루빈서 답 찾는다”

블로터와 한국바이오협회가 바이오 기업을 만나 산업이슈를 조명합니다. “도전이 없으면 신약도 없다고 생각한다. 누군가는 허혈성재관류손상 치료라는 어려운 과제에 도전을 해야하며, 빌릭스는 기술적으로 준비돼있다.” 국내제약바이오 기업에게 세계 최초(First-in-class) 치료제 개발은 중요한 가치를 가진다. First-in-class

Collaborators

We work closely with our collaborators in all aspects of drug development and commercialization including research organizations, clinical development entities, hospitals, intellectual property experts, patient advocate groups, and governments. Our ambition is to improve patient health and care. If you are interested in collaborating with us, please contact us.